Recently, Boston Scientific Corporation announced,The FARAPULSE™ series of pulsed field ablation products under its portfolio, including the FARAWAVE single-use cardiac pulsed field ablation catheter and the FARASTAR cardiac pulsed field ablation system, have received approval from the National Medical Products Administration (NMPA).

AsThe World's FirstThe pulsed field ablation (PFA) product that has been listed and commercialized, FARAPULSE, received the "Breakthrough Device Designation" from the U.S. FDA as early as 2019, and was officially approved for listing by the EU CE in 2021. This time, it has once again received NMPA approval.Marks that this innovative technology will lead the field of atrial fibrillation treatment in China into a new energy era.

The situation of atrial fibrillation prevention and treatment in China is severe. According to the 2022 research data from The Lancet's subsidiary journal, in ChinaNearly 20 Million Patients with Atrial Fibrillation, affected by the aging population, the number of patients is expected to further increase in the future.

Currently, catheter ablation has become the main treatment method for maintaining sinus rhythm in patients with atrial fibrillation. However, due toTraditional Catheter Ablation(Including radiofrequency ablation and cryoablation) carries the risk of serious surgical complications such as pulmonary vein stenosis, left atrial-esophageal fistula, and phrenic nerve injury.

How to perform atrial fibrillation catheter ablation surgery more safely and effectively is an important pain point困扰 clinical practice.

As a latecomer in the atrial fibrillation field, Boston Scientific has pioneered its entry.PFA Research Field，A New Treatment Approach for Atrial Fibrillation Ablation – PFA (Pulse Field Ablation), which is also the most promising next-generation atrial fibrillation ablation technology in the field of electrophysiology.

Fundamentally different from traditional thermal ablation methods such as radiofrequency and cryoablation, the greatest advantage of PFA is its ability toSelective Ablation of Target Cardiac Muscle Cells, without causing much impact on the surrounding tissues, blood vessels, and nerves. Moreover, the FARAPULSE system is especially suitable for pulmonary vein isolation when treating refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation (AF).Is a unique and innovative alternative to standard thermal ablation therapy.

Since its establishment, Boston Scientific has been defining, optimizing, and validating pulsed field ablation therapy, with the design goal of ensuring patient safety and meeting the needs of physicians. The Farapulse system has undergone extensive clinical research and boasts the largest body of published clinical evidence.

The ADVENT Pivotal Trial is the first randomized clinical trial to directly compare PFA with traditional thermal ablation devices.Showed that the Farapulse system met the primary safety and effectiveness endpoints, with shorter procedure times and no severe thermal complications.

In addition,No cases of permanent phrenic nerve paralysis, pulmonary vein stenosis, or esophageal injury were reported in the real-world data of over 17,000 patients from the MANIFEST-17K registry study.Currently, FARAPULSE has been approved in Europe and the United States, and to date, it has treated more than70,000 patients.

The approval of the FARAPULSE series by the NMPA marks a new era in the treatment of atrial fibrillation in China, led by this innovative technology. It is also expected that in the near future, this globally leading medical technology achievement will benefit more patients with atrial fibrillation in China.

As "the leading technology in cardiac ablation for the next decade," the pulsed field ablation market has enormous growth potential.

According to FMI data, from 2021 to 2022, the global pulsed field ablation market achieved a compound annual growth rate as high as 48.6%, with the market size reaching 1.3 million US dollars by 2023.

To maintain a competitive edge in the PFA market, Boston Scientific needs to act at the critical junctures of industrial upgrading.Continuously expand overseas markets and enhance the brand's competitiveness.

The approval of FARAPULSE in the Chinese market this time is an important step for Boston Scientific Corporation to reach a milestone, opening up and entering a vast and largely untapped market.

In fact, to further consolidate its leading position in the global cardiovascular medical field and seek broader development in this fertile land, Boston Scientific set its sights on the high-potential Chinese market at an early stage, meticulously building a new "heart" landscape.

To promote the successful launch of the FARAPULSE system in China, Boston Scientific has taken frequent actions in recent years.

Successively passed"Pilot Policy, Guangdong-Hong Kong-Macao Medical Device Access Policy"Equal Path, Explore the Early Clinical Application of the FARAPULSE System in China.

And these explorations have been highly effective:

It can be said that the rapid launch of FARAPULSE in China is a two-way synergy between Boston Scientific's disruptive innovation technology and China's supportive policies, markingThis innovative technology will cover China, a high-potential emerging market., leading the field of atrial fibrillation treatment in China to accelerate into the PFA era.

Besides, the expansion of the Chinese market is also an important part of Boston Scientific Corporation's global strategy. The company has already seen significant adoption and market success in Europe and the United States, and the approval in China is expected to...Further increase its market penetration and sales.

According to Boston Scientific's 2023 annual financial report, in the revenue of $14.24 billion (approximately 101.1 billion RMB), the core business segment — cardiovascular business revenue was $5.422 billion, a year-on-year increase of 13%. Electrophysiology, as one of the five细分 fields of cardiovascular business,Revenue of $800 million, ranking first with a growth rate of 33%.

The rapid growth of electrophysiology financial data is directly related to the CE approval and rapid market uptake of FARAPULSE PFA in Europe. According to Boston Scientific CEO Mahoney, since FARAPULSE PFA received CE approval,Helped Boston Scientific Corporation's global electrophysiology revenue grow by 46% in the fourth quarter of 2023.

The approval of Boston Scientific's FARAPULSE pulsed field ablation (PFA) system by the NMPA will undoubtedly accelerate its market expansion in China andSignificantly ImproveBoston Scientific Corporation's Electrophysiology Sales.

CEO Mike Mahoney described FARAPULSE as one of the company's most transformative products, expecting its ease of use, safety, and effectiveness to replicate success in the Chinese market, leading Boston Scientific to new strategic heights.

It is predicted that the global atrial fibrillation ablation market will double by 2028, reaching 11 billion yuan. Among this, as a major demand country, China has more than 10 million patients with atrial fibrillation. In the cardiac electrophysiology market, data from the National Health Commission's Arrhythmia Intervention Quality Control Center shows: The number of surgeries using ablation treatment for arrhythmia patients in China reached336,000 cases, with a compound annual growth rate of 17.3%.

Under the vast number of patients and surgeries, a broader PFA market space in China has been spurred. According to Frost & Sullivan, the scale of China's PFA market is expected to reach 1.3 billion yuan by 2025, maintaining rapid growth, and projected to reach by 2032.16.3 billion yuan, with a CAGR of 43.73% during the period.

At the same time, the proportion of China's PFA market size in the overall electrophysiology device market size is also expected to continue rising, increasing from 8.18% in 2025 to 38.87% in 2032.

The exaggerated growth data of FARAPULSE is enough to explain why the electrophysiology giants are scrambling to lay out in the PFA field. Looking at the PFA market in China, besides this timeBoston ScientificApproval of the product,Medtronic, Johnson & JohnsonMultinational medical device companies have all started to lay out related product pipelines.

The rapid expansion of the PFA market in China,Not only accelerated the competition among overseas giants, but also promoted the breakthrough of domestically produced products.

Currently, in ChinaJinjiang ElectronicsPulse Field Ablation System Independently Developed Receives NMPA Approval for Market LaunchDenovo EPThe self-developed petal-shaped cardiac pulse field ablation catheter, CardiPulse, was also approved for marketing by the NMPA in March 2024, becoming the second cardiac pulse field ablation system to gain NMPA approval.

In addition,Northcore Life, Ruidi Biotech, Aikema, Xuanyu Medical, Maiwei Medical, Denovo EP, Hongtong Industry, Epflex (a subsidiary of Huitai Medical), Shangyang MedicalPFA products from innovative Chinese companies such as MicroPort EP (a subsidiary of MicroPort) have entered the NMPA special review process, while approximately 50 other companies are accelerating the development of PFA cardiac ablation systems.

It is expected that the 9 domestically produced PFA products that have entered the green channel, along with the 3 PFA products from multinational giants, will soon be approved. At that time, there will be more than 12 PFA products competing in the Chinese market.

It can be seen that in this market competition centered around PFA, Chinese-produced brands have officially taken the stage.

And with the approval of Boston Scientific's FARAPULSE in China, the much-anticipated PFA battle extends from overseas to within China.This will inevitably trigger a market battle between domestically produced and imported products in China.

As the world's second-largest medical device market, China is almost one of the most competitive markets globally. Facing multinational giants with advantages in capital, brand, and channels,Are domestic companies confident in fighting a market battle?

From a global perspective, PFA is also an emerging technology, with relatively small accumulated gaps between China and foreign countries. Local brands are expected to secure their place in future market competition.

First, in ChinaIn terms of PFA layout, PFA products from Chinese manufacturers will obtain NMPA approval earlier, securing a first-mover market advantage.

PFA products from China-based companies such as Aikangmai, Ruidi Biotech, and Beixins Life generally started clinical trials in China earlier than multinational giants. Aikangmai expects its PFA product to be approved in China 1-2 years ahead of similar products from Johnson & Johnson, Abbott, and Medtronic, securing a first-mover advantage.

Secondly, in terms of national policy, domestically produced medical devices can be given priority in procurement.

According to the policies such as the "Planning Outline for the National Medical and Health Service System" issued by the state, there is a clear requirement to gradually increase the configuration level of domestically produced medical equipment in China. It specifies that the Drug Administration, the Health Commission, and the Medical Insurance Bureau are responsible for promoting the localization of medical devices. Additionally, regions such as Fujian, Sichuan, and Hubei have also explicitly prioritized the procurement of domestically produced medical devices during the bidding process.

At the same time inUnder the advancement of centralized procurement, electrophysiological medical devices have already undergone multiple rounds of testing.As of the end of August 2023, high-value consumables for electrophysiology have been subjected to 11 provincial-level centralized procurement processes nationwide in China.Led by Fujian ProvinceThe "27+15" Alliance and the Beijing-Tianjin-Hebei "3+N" Alliance have launched large-scale national alliance procurement, covering nearly the entire Chinese market. However, under relatively moderate procurement rules, domestic manufacturers have also quickly achieved volume through price reductions.

Finally, domestic manufacturers inPFA Product Development Has Unique Advantages.

On the one hand, the product development costs of companies in ChinaProduction CostHas obvious advantages over international counterparts. On the other hand, it canFaster Response to Market Demand in China, and make timely adjustments and optimize the product.Such as:

This shows that, under the ambitious attacks of foreign-funded enterprises, Chinese-produced enterprises have ignited their fighting spirit to continuously advance on the path of technological innovation.

In the increasingly competitive PFA market in China, Boston Scientific has only just secured its entry ticket.Can the highly anticipated FARAPULSE pulsed field ablation product successfully break through under the pursuit and encirclement of many powerful Chinese-produced competitors?How will Boston Scientific formulate its commercialization strategy in China? We will continue to follow up!

Boston Scientific Product Interest Registration

If you are interested in this Boston Scientific product

You can scan the code to register~